Society for Immunotherapy of Cancer (SITC2021) BMY Abstracts 10-14Nov2021 | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  8153 of 8526  at  10/17/2021 6:39:05 PM  by

JBWIN


Society for Immunotherapy of Cancer (SITC2021) BMY Abstracts 10-14Nov2021

 
 
#TypeTitleAuthorsCategoryKeywords
106Poster PresentationTreatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel)Archana Brahmandam, MS; Jim J. Qin, BS; Susan Kim; Yue Jiang; Brook Barajas; Soraya Carrancio; Leanne PeiserCellular TherapiesCAR T cells;Cytokine;Gene expression;Leukemia/Lymphoma;T cell;Targeted therapy
449Oral PresentationConcurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapyJerill Thorpe, M.S.; Julie A. Rytlewski; Heidi H. Gillenwater; Ken Ogasawara; Yeonhee Kim; Diana Shpektor; Eniko Papp; Leanne PeiserClinical Trials In ProgressCAR T cells;Gene expression;Leukemia/Lymphoma;T cell;Targeted therapy
 

cereblon E3 ubiquitin ligase modulating agent CC-99282 (CELMoD)

A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, cereblon E3 ubiquitin ligase modulating agent CC-99282 specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T cells. This leads to modulation of the immune system, including activation of T lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.
 
#TypeTitleAuthorsCategoryKeywords
478Poster PresentationCOM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab - preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)Ecaterina E. Dumbrava, MD; Manish R. Sharma, MD; Gini Fleming, MD; Kyriakos P. Papadopoulos, MD; Ryan J. Sullivan, MD; Daniel Vaena; Amita Patnaik, MD; Adam ElNaggar; Adeboye H. Adewoye, MD; Robina Smith; Pierre Ferré, Dr Vet Med; Inbal Barbiro; Emerson Lim, MD.; Drew Rasco, MDClinical Trials In ProgressAntibody;Checkpoint blockade;Clinical study;Clinical trial;T cell
 

#TypeTitleAuthorsCategoryKeywords
24Poster PresentationNivolumab Serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome.Domenico Mallardo, MD; Maria Grazia Vitale, MD; Diana Giannarelli, MD; Giusy Trillò; Assunta Esposito, PhD; Mariaelena Capone, MD; Maria Antonietta Isgrò; Gabriele Madonna, MS; grazia d'angelo; Lucia Festino; Vito Vanella; Claudia Trojaniello; Alessandro Manzoni; Andrew M. White, BSc; Michael Bailey; Ester Simeone, MD; Corrado Caracò; Piera Maiolino; Nicola Normanno; Sarah E. Warren, PhD; Ernesta Cavalcanti; Paolo A. Ascierto, MDBiomarkers, Immune Monitoring, and Novel TechnologiesAntibody;Antigen presenting cells;Biomarkers;Checkpoint blockade;Gene expression;Immune suppression;T cell
27Poster PresentationCytokine signature of PD-1, CXCL10, and TNF-alpha predicts response to nivolumab and ipilimumabJesper G. Pedersen; Mateo Sokac; Nicolai J. Birkbak; Trine H. Øllegaard; Martin R. JakobsenBiomarkers, Immune Monitoring, and Novel TechnologiesBiomarkers;Checkpoint blockade;Cytokine
59Poster PresentationAssociations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trialArika S. Feils, BS; Amy K. Erbe, PhD; Jen Birstler; KyungMann Kim, PhD; Ute Hoch, PhD; Sue L. Currie, PhD; Tuan Nguyen, PhD; Danni Yu; Arlene O. Siefker-Radtke, MD; Nizar M. Tannir, MD, FACP; Matthew D. Hellmann, MD; Sara Tolaney; Adi Diab, MD; Paul M. Sondel, MD, PhDBiomarkers, Immune Monitoring, and Novel TechnologiesBiomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Genetic polymorphism;NK/NKT cell;Solid tumors
277Poster PresentationSafety and Efficacy of Intratumoral Ipilimumab with IV Nivolumab in Metastatic Melanoma. The NIVIPIT Trial.Lambros Tselikas, MD; Caroline Robert, MD, PhD; Stephane Dalle; Nicolas Meyer; Celeste Lebbe, MD, PhD; Samy Ammari; François-Xavier Danlos; Severine Roy; Camille Jannin; Siham Farhane; Severine Mourad; Guillaume Escriou; Thibault Raoult; Jean-Yves Scoazec, MD; Matthieuu Texier; Nathalie Chaput-Gras; Laurence Zitvogel, MD, PhD; Thierry De Baere, MD, PhD; Aurélien MarabelleCheckpoint Blockade TherapyAntibody;Biomarkers;Checkpoint blockade;Chemokine;Immune monitoring;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment
313Poster PresentationStealthier mutanomes are induced after nivolumab immunotherapyGuilhem Richard, PhD; Michael F. Princiotta, PhD; Gary D. Steinberg, MD; William Martin, BA MD; Anne S. de Groot, MDCheckpoint Blockade TherapyBioinformatics;Checkpoint blockade;Immune tolerance;Neoantigens;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor evasion
340Poster PresentationA phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC)Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Keith Dredge, PhD; Darryn Bampton; Edward Hammond; Amanda Stanley; Lucie Leveque-ElMouttie; Grace Chojnowski; Andrew M. Haydon, PhD; Nick Pavlakis; Matthew Burge; Michael P. Brown; David GoldsteinClinical Trials CompletedBiomarkers;Checkpoint blockade;Clinical trial;Solid tumors;T cell;TLR
341Poster PresentationA phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC).Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Keith Dredge, PhD; Darryn Bampton; Edward Hammond; Andrew Clouson; Nigel Waterhouse; Amanda Stanley; Lucie Leveque-ElMouttie; Grace Chojnowski; Andrew M. Haydon, PhD; Nick Pavlakis; Matthew E. Burge; Michael P. Brown; david goldstein, MDClinical Trials CompletedBiomarkers;Checkpoint blockade;Clinical trial;Dendritic cell;T cell;TLR;Tumor infiltrating lymphocytes (TILs)
342Poster PresentationCombining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 studyDavid Krige, PhD; Marwan Fakih; Lee Rosen; Ding Wang, MD; Wael A. Harb, MD, CPI; Hani Babiker; Jordan Berlin, MD; Gianfranco Di Genova; David Miles; Mark Powell; Minesh Patel; Jo Carter; Richard A. Brown, PhD; Tom Lillie, MD PhDClinical Trials CompletedCheckpoint blockade;Clinical study;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
343Poster PresentationMultiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer.Deena M. Maurer, PhD; Jia Xin Yu, PhD; Kamil Sklodowski, PhD; Marco Tognetti, PhD; Lukas Reiter, PhD; Roland Bruderer, PhD; Jakob Vowinckel, PhD; Shannon M. Pfeiffer, MS; Mark H. O'Hara, MD; Eileen M. O’Reilly, MD; Robert A. Wolff, MD; Zev A. Wainberg, MD; Andrew H. Ko, MD; Osama Rahm, MD; George A. Fisher, MD; Jaclyn P. Lyman, MS; Christopher R. Cabanski, PhD; Pier Federico Gherardini, PhD; Jill O’Donnell-Tormey, PhD; Theresa M. LaVallee, PhD; Robert H. Vonderheide, MD, PhD; Lacey J. Kitch, PhDClinical Trials CompletedBiomarkers;Checkpoint blockade;Chemokine;Chemotherapy;Clinical trial;Costimulation;Immune suppression;Solid tumors
389Poster PresentationPhase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 TherapySarah A. Weiss, MD; Mario Sznol, MD; Montaser Shaheen, MD; Miguel-Ángel Berciano-Guerrero, MD, PhD; Enriqueta Felip, MD, PhD; Delvys Rodríguez-Abreu, MD; Ana Maria Arance, MD, PhD; Valentina Boni, MD, PhD; Gerald P. Linette, MD, PhD; Lynn M. Schuchter, MD; Maria Gonzalez-Cao, MD, PhD; Nicholas O. Iannotti, MD; Apar Kishor Ganti, MD, MS; Ralph J. Hauke, MD; Alfonso Berrocal, MD; Erin L. Filbert, PhD; Harriet M. Kluger, MDClinical Trials CompletedAntibody;Antigen presenting cells;Clinical trial;Costimulation;Solid tumors
392Poster PresentationA Phase 1a/b Study of IK-175, an Oral AHR Inhibitor, Alone and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaMeredith McKean, MD; Jason J. Luke; Nehal J. Lakhani, MD; Babar Bashir, MD, MS; David H. Aggen, MD, PhD; Alan Tan, MD; Katherine Kacena, PhD; Lei Wang, PhD; Marissa Timothy, MS; Sergio L. Santillana, MD, MSc, MBAClinical Trials In ProgressBiomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
399Poster PresentationA phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancerDavid B. Page, MD; Krystle L. Collins, MD; Brie M. Chun, MD; Zhaoyu Sun, Ph.D.; Yoshinobu Koguchi, MD, PhD; William L. Redmond, Ph.D.; Maritza Martel, MD; Yaping Wu, MD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Walter J. Urba, MD, PhD; Ayca Gucalp, MD; Tiffany A. Traina, MDClinical Trials In ProgressBiomarkers;Checkpoint blockade;Clinical trial;Immune adjuvant;Solid tumors;T cell;Tumor microenvironment
420Poster PresentationPROSTVAC in combination with Nivolumab enhanced immune cell infiltration in prostate cancer.Shania A. Bailey, BS; Wiem Lassoued, PhD; Antonios Papanicolau-Sengos, MD; Jennifer L. Marte, MD, MPH; Nikki Williams; amy hankin; michell manu; William Dahut, MD; peter pinto; Fatima Karzai, MD; Ravi A. Madan, MD; Houssein Abdul Sater, MD; James L. Gulley, MD, PhDClinical Trials In ProgressCheckpoint blockade;Clinical trial;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
478Poster PresentationCOM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab - preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)Ecaterina E. Dumbrava, MD; Manish R. Sharma, MD; Gini Fleming, MD; Kyriakos P. Papadopoulos, MD; Ryan J. Sullivan, MD; Daniel Vaena; Amita Patnaik, MD; Adam ElNaggar; Adeboye H. Adewoye, MD; Robina Smith; Pierre Ferré, Dr Vet Med; Inbal Barbiro; Emerson Lim, MD.; Drew Rasco, MDClinical Trials In ProgressAntibody;Checkpoint blockade;Clinical study;Clinical trial;T cell
506Poster PresentationIGNYTE: An open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumorsMark R. Middleton, MD, PhD; Mohammed M. Milhem, MBBS; Francesca Aroldi, MSc; Joseph J. Sacco, MD PhD; Ari M. VanderWalde, MD, MPH, MBioeth; Scott Baum; Adel Samson, PhD; Jason A. Chesney, MD; Jiaxin Niu; Terence Rhodes, MD, PhD; Tawnya L. Bowles, MD; Hamid Emamekhoo, MD; Katy K. Tsai, MD; Gino K. In, MD, MPH; Georgia M. Beasley, MD, MHs; Bartosz Chmielowski; Sophie Dalac-Rat, MD; Katharina Kahler; Eva Muñoz, MD, PhD; Anna C. Olsson-Brown, MD; Praveen K. Bommareddy, MS, PhD; Lavita Menezes, MSc; Andrea Pirzkall, MD; Robert S. Coffin, PhD; Kevin Harrington, PhD, FRCP, FRCRClinical Trials In ProgressB cell;Clinical trial;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
507Poster PresentationA phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumorsMark R. Middleton, MD, PhD; Joseph J. Sacco, MD PhD; Kevin Harrington, PhD, FRCP, FRCR; Anna C. Olsson-Brown, MD; Tze Y. Chan, MBChB; Pablo Nenclares; Isla Leslie; Francesca Aroldi, MSc; Praveen K. Bommareddy, MS, PhD; Imran Saleem; Henry Castro; Andrea Pirzkall, MD; Robert S. Coffin, PhDClinical Trials In ProgressB cell;Checkpoint blockade;Clinical study;Neoantigens;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
586Poster PresentationMonitoring the impact of MDSC targeting drugs in combination with nivolumab on activation and proliferation of tumor resident effector immune cells in patient-derived 3D-EXplore platformJared C. Ehrhart, PhD; Brittany Bunch; Kelly Sussman; Kelly Guzman; Soner Altiok, MD, PhDCombination ImmunotherapiesCheckpoint blockade;Costimulation;Immune suppression;MDSC;Solid tumors;Tumor evasion;Tumor microenvironment;Tumor stroma
759Poster PresentationSingle-Cell Proteogenomics (Cite-seq) analysis of cGAS-STING pathway activation alone and in combination with nivolumab using a patient-derived 3D ex vivo tumoroid platformBrittany Bunch, PhD; Autumn Joerger, PA; Nino Mtchedlidze; Olivia Hoff; Kelly Guzman; Jared C. Ehrhart, PhD; Soner Altiok, MD, PhDImmune-stimulants and immune modulatorsCheckpoint blockade;Gene expression;RNA;Solid tumors;Tumor microenvironment;Tumor stroma
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 5  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...